Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04800562 · ClinicalTrials.gov registry record · Phase 2
A Clinical Trial to Evaluate PCS499 in Treating Ulcerations in Patients Who Have Necrobiosis Lipoidica
A Phase 2 study, sponsored by Processa Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT04800562 is a Phase 2 study that was terminated before completion, run by Processa Pharmaceuticals. The registered enrollment target is 4 participants.
The verdict
NCT04800562, a Phase 2 study, was terminated before completion, sponsored by Processa Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
This is a randomized, double blind, placebo controlled study that will evaluate the efficacy and safety of PCS499 as compared to placebo for the treatment of ulcerations of patients with necrobiosis lipoidica (NL) and will inform the design of future studies. Approximately 20 ulcerated NL patients who also meet other inclusion/exclusion criteria will be enrolled in the study. The primary objective of this study is to evaluate the efficacy of PCS499 as compared with placebo in ulcerated patients with Necrobiosis Lipoidica.
Interventions
- OTHER placebo
- DRUG PCS499
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2021-04-12 |
| Est. Completion | 2023-04-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04800562
The ClinicalTrials.gov registry entry for NCT04800562 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Processa Pharmaceuticals, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT04800562 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04800562 about?
NCT04800562 is a clinical study titled "A Clinical Trial to Evaluate PCS499 in Treating Ulcerations in Patients Who Have Necrobiosis Lipoidica". This is a randomized, double blind, placebo controlled study that will evaluate the efficacy and safety of PCS499 as compared to placebo for the treatment of ulcerations of patients with necrobiosis lipoidica (NL) and will inform the design of future studies. Approximately 20 ulcerated NL patients w...
What is the current status of trial NCT04800562?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2021-04-12. Estimated completion is 2023-04-14.
What interventions are being tested in trial NCT04800562?
The interventions under investigation include: placebo (OTHER), PCS499 (DRUG).
Who is sponsoring clinical trial NCT04800562?
This trial is sponsored by Processa Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.